Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Stemline Therapeutics Inc. STML

Healthcare Biotechnology
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an... see more

Recent & Breaking News (NDAQ:STML)

Stemline Therapeutics to Present at the 27th Annual ROTH Conference

GlobeNewswire March 6, 2015

Stemline Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference

GlobeNewswire February 26, 2015

Stemline Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference

GlobeNewswire February 4, 2015

Stemline Therapeutics Announces SL-701 Granted Orphan Drug Designation for the Treatment of Glioma

GlobeNewswire January 30, 2015

Stemline Therapeutics Prices $59.85 Million Public Offering of Common Stock

GlobeNewswire January 8, 2015

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire January 7, 2015

Stemline Therapeutics In-Licenses Novel Oral Small Molecule Nuclear Transport Inhibitor Targeting XPO1

GlobeNewswire January 7, 2015

Stemline Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 29, 2014

TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors

GlobeNewswire December 17, 2014

Stemline Therapeutics Initiates SL-401 Clinical Trial in Four Rare Myeloproliferative Neoplasms

GlobeNewswire December 16, 2014

Stemline Therapeutics Announces Multiple Preclinical Presentations Highlighting Its Pipeline of IL-3R-Directed Therapeutics at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 5, 2014

Stemline Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2014

Stemline Therapeutics to Participate in the Barclays Select Series Symposium

GlobeNewswire November 10, 2014

Stemline Therapeutics Initiates SL-401 Trial in AML Patients in First Complete Response With Minimal Residual Disease, the Second SL-401 Trial Initiated in 2H14

GlobeNewswire October 16, 2014

Stemline Therapeutics Inc. (STML) Jumps 5.99% on September 10

Equities.com September 10, 2014

Stemline Therapeutics to Present at the Aegis Capital 2014 Healthcare & Technology Conference

GlobeNewswire September 8, 2014

Stemline Therapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

GlobeNewswire September 4, 2014

Stemline Therapeutics Provides Second Quarter 2014 Financial Results and Corporate Update

GlobeNewswire August 14, 2014

Leading Health Care Stock for Small-Cap Stars is Boston Therapeutics Inc (BTHE) for August 11

Equities.com August 11, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014